News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
Presentation ESC 2021 Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Presenter: Renato D. Lopes August 31, 2021
News Conference News ESC 2021 PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer Michael O'Riordan August 30, 2021
News Conference News ESC 2021 IAMI: Influenza Vaccine Beneficial for Post-MI Patients Michael O'Riordan August 30, 2021
News Conference News ESC 2021 Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD Michael O'Riordan August 28, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021